SABCS 2021

Critical consideration of the study data is necessary

Genomic signatures of DCIS

Metformin shows no efficacy for most cancer patients

The risk-adapted decision for or against AI has to be…

Leading the way for other ct-DNA trials

Molecular-guided treatment is of value in combination…

Benefit only related to chemotherapy?!

Negative results with hope for translational projects

Re-evaluation confirms old data

Metformin is not an anti-cancer drug

Solved and unsolved controversies of early breast…

Hypothesis-generating study in the HER2-enriched…

The next standard for TNBC?!

E’ solo effetto della chemioterapia?

Negative Ergebnisse, aber Hoffnung für translationale…

La metformina non può essere considerata un farmaco…

Muss die risiko-adaptierte Entscheidungsfindung bei AI…

"Signatures Genomiche " nel carcinoma duttale in situ

Genomisch gesteuererte Therapie sinnvoll in Kombi mit…

Hypothesen-generierende Studie beim HER2-enriched…

Erneute Auswertung bestätigt alte Daten

RxPONDER: Benefit only for pre-menopausal patients?…

KEYNOTE-522 confirms ICI benefit in the neoadjuvant…

MOLECULAR DIAGNOSTICS EBC: ctDNA for early detection of…

TNBC EBC: What is the new neoadjuvant standard…

HR+ EBC: What about PALLAS/PENELOPE-B? What is the…

Dato-Dxd for metastatic TNBC

Oral SERDs for early setting and adjuvant therapy

Effectiveness depending on PDL1 status

Samuraciclib - new targeted therapy for luminal breast…

3 updates - 3 new standards of care

Oral SERDs are efficient, but show high progression…

My highlights of 2021 in metastatic breast cancer

TROP2 - new target for improved chemotherapy

TDXd is very efficient in patients with brain…

Immuntherapy for high tumor mutation burden in…

Pooled analyses shows OS benefit for most subgroups

Dato-DXd new promising ADC

Very good news for endocrine resistant metastatic…

Amazing period for patients with refractory metastatic…

PFS improvement with fulvestrant in patients with…

T-Dxd is also active in patients with brain metastasis

Reconfirming effect of T-DXd in patients with brain…

Imaging with mass cytometry can provide predictive…

Activity of T-Dxd across all Her2-expressing breast…

IO + IO without resounding success in the mBC setting

Patients with BRCA2 don't show PFS benefit with CDK4/6i

Elacestrant - less than we expected

Switching with molecular progress improves PFS

Final results of the CPS score subgroup analyses show…

Exciting novel therapies for metastatic TNBC

Promising results for TNBC patients

Robust benefit of pembroluzimab in addition to…

Precision oncology is beneficial in certain mBC…

Which patients will benefit from Pembro in metastatic…

More good news for TDXd

Pioneering study of personalized medicine in advanced…

Best of the year: systemic therapy

Risultati promettenti nel tumore al seno triplo…

Résultats prometteurs dans le cancer du sein triple…

IO + IO ohne durchschlagenden Erfolg beim mBC

TDXd zeigt große Wirksamkeit bei Hirnmetastasen

Gepoolte Analyse zeigt OS Vorteil für fast alle…

HER2 Patientinnen mit BRCA2 Mutation haben PFS Nachteil…

L’imaging mass cytometry può aiutare a predire…

Umstellung bei molekularem Progress verlängert PFS

Neues Target für optimierte Chemotherapie

Präzisionsonkologie funktioniert beim mBC

Resultados finales de los análisis de los subgrupos de…

È un grande momento per i pazienti con tumore mammario…

Wegweisende Daten für die personalisierte Medizin beim…

Dato-DXd – nowy obiecujący koniugat przeciwciała i…

Activité du T-DXd dans les metastases cérébrales

Buone notizie per i tumori mammari endocrino resistenti

Samuracyklib – nowe leczenie celowane w rakach…

Checkpoint-Inhibition beim Mammakarzinom

T-Dxd aktywny również w przerzutach do mózgu

Important benefice de l’ajout du pembrolizumab à la…

Mi retrospectiva del cáncer de mama metastático en 2021

Best of the Year: Systemtherapie

Wirksamkeit in Abhängigkeit von PDL1-Stautus

Werden orale SERDs die Therapie mit Fulvestrant in…

Elacestrant – poniżej oczekiwań

Amélioration de la survie sans progression par le…

MBC TNBC: Molecular tumor characteristics define the…

Integrating patients perspectives in metastatic breast…

MBC HR+: What is the best option after a CDK4/6i…

Targeting rare mutations in breast cancer - is this the…

Treatment options for patients with metastatic TNBC

New ADCs on the horizon for TNBC patients

Therapy of brain metastasis – can T-DXd be the new SoC?